Cardiovascular: Pericardial effusion and occasionally with tamponade (3%). Changes in direction and magnitude of T waves occur (approximately 60%).
GI: Nausea, vomiting.
Hematologic: Initially, hematocrit, hemoglobin, and erythrocyte count usually fall about 7% and then recover to pretreatment levels. Thrombocytopenia and leukopenia (WBC fewer than 3,000/mm3) have been reported rarely.
Hypersensitivity: Rashes including bullous eruptions (rare) and Stevens-Johnson syndrome.
Lab test abnormalities: Alkaline phosphatase increased varyingly without other evidence of liver or bone abnormality. Serum creatinine increased an average of 6% and BUN slightly more but later declined to pretreatment levels.
Miscellaneous: Temporary edema (7%); breast tenderness (fewer than 1%).
Hypertrichosis: Elongation, thickening, and enhanced pigmentation of fine body hair develops within 3 to 6 weeks of starting therapy in approximately 80% of patients.